Titan Medical to Report First Quarter 2021 Financial Results May 17, 2021
May 04 2021 - 7:30AM
Business Wire
Titan Medical Inc. (“Titan” or the “Company”)
(TSX: TMD) (Nasdaq: TMDI), a medical
device company focused on the design and development of surgical
technologies for robotic single access surgery, announces that the
Company plans to issue its first quarter financial results prior to
market opening Monday, May 17, 2021 and management will host an
investor audio webcast at 4:30 p.m. ET to discuss financial results
and business highlights. Speakers will include David J. McNally,
President and Chief Executive Officer, Monique L. Delorme, Chief
Financial Officer, and Perry A. Genova, Ph.D., Senior Vice
President, Research and Development.
A link to the live audio webcast will be made available on the
"Investor Relations" section of the Company’s website,
www.titanmedicalinc.com. A webcast replay will be archived and
accessible on the Company’s website shortly after conclusion of the
live audio webcast.
About Titan Medical
Titan Medical Inc., a medical device company headquartered in
Toronto, is focused on developing robotic assisted technologies for
application in single access surgery. The Enos™ system, by Titan
Medical, is being developed with dual 3D and 2D high-definition
vision systems, multi-articulating instruments, and an ergonomic
surgeon workstation. With the Enos system, Titan intends to
initially pursue gynecologic surgical indications.
Certain of Titan’s robotic assisted surgical technologies and
related intellectual property have been licensed to Medtronic plc,
while retaining world-wide rights to commercialize the technologies
for use with the Enos system.
Enos™ is a trademark of Titan Medical Inc.
For more information, please visit www.titanmedicalinc.com.
Forward-Looking Statements
This news release contains “forward-looking statements” within
the meaning of applicable Canadian and U.S. securities laws, which
reflect the current expectations of management of the Company’s
future growth, results of operations, performance, and business
prospects and opportunities. Wherever possible, words such as
“may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”,
“expect”, “intend”, “estimate”, “potential for” and similar
expressions have been used to identify these forward-looking
statements, including, without limitation, references to: the
Company’s focus on the design and development of surgical
technologies for robotic single access surgery, the Enos system is
being developed with dual 3D and 2D high-definition vision systems,
multi-articulating instruments and an ergonomic surgeon
workstation, and that Titan intends to initially pursue gynecologic
surgical indications. These statements reflect management’s current
beliefs and are based on information currently available to
management. Forward-looking statements involve significant risks,
uncertainties and assumptions. Many factors could cause the
Company’s actual results, performance or achievements to be
materially different from any future results, performance or
achievements that may be expressed or implied by such
forward-looking statements, including, without limitation, those
listed in the “Risk Factors” section of the Company’s Annual
Information Form and Form 40-F for the fiscal year ended December
31, 2020 (which may be viewed at www.sedar.com and at www.sec.gov).
Should one or more of these risks or uncertainties materialize, or
should assumptions underlying the forward-looking statements prove
incorrect, actual results, performance, or achievements may vary
materially from those expressed or implied by the forward-looking
statements contained in this news release. These factors should be
considered carefully, and prospective investors should not place
undue reliance on the forward-looking statements. Although the
forward-looking statements contained in the news release are based
upon what management currently believes to be reasonable
assumptions, the Company cannot assure prospective investors that
actual results, performance or achievements will be consistent with
these forward-looking statements. Except as required by law, the
Company expressly disclaims any intention or obligation to update
or revise any forward-looking statements whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210504005446/en/
Kristen Galfetti Vice President Investor Relations
+1-781-869-2553 investors@titanmedicalinc.com
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From Sep 2023 to Sep 2024